According to documents submitted to the U.S. Securities and Exchange Commission, Centessa Pharmaceuticals plc announced that a key closing condition for its transaction with Eli Lilly has been satisfied—the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

According to documents submitted to the U.S. Securities and Exchange Commission, Centessa Pharmaceuticals plc announced that a key closing condition for its transaction with Eli Lilly has been satisfied—the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

老虎证券2026/05/22 21:01

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This development marks a significant step toward the final completion of the transaction. The expiration of the HSR Act waiting period has removed a major regulatory obstacle facing the transaction, clearing the way for both parties to proceed with the next steps. Other customary closing conditions for the transaction, including obtaining shareholder approval, still need to be satisfied. Both parties will continue to focus on completing the transaction within the agreed timeframe.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to documents submitted to the U.S. Securities and Exchange Commission, Centessa Pharmaceuticals plc announced that a key closing condition for its transaction with Eli Lilly has been satisfied—the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

You may also like

Trending news

Crypto prices